Articles related to ANTIPSYCHOTICS

A narrative review and accompanying expert commentary outlined diagnostic features distinguishing substance-induced psychosis from primary psychotic disorders amid rising cannabis and stimulant exposure.

The Tardive Dyskinesia Impact Scale showed high discrimination and precision across physical function and socioemotional domains in pooled data from 388 patients in the KINECT 3 and KINECT 4 valbenazine trials.

A JAMA Psychiatry network meta-analysis ranked lumateperone highest for efficacy and aripiprazole highest for acceptability among five FDA-approved adjunctive atypical antipsychotics for major depressive disorder.

A Rhode Island court denied summary judgment in an informed consent suit after a patient developed permanent tardive dyskinesia following an intra-class antipsychotic switch.

VMAT2 inhibitors were associated with lower rates of falls, injuries, fractures, and several secondary adverse outcomes than anticholinergic agents in a propensity-matched cohort of adults with tardive dyskinesia.

The FDA approved a supplemental NDA adding randomized withdrawal trial data to the lumateperone label, supporting its role in long-term maintenance and relapse prevention in adults with schizophrenia.